India Decides Fighting Tuberculosis Is More Important Than Johnson & Johnson’s Profits

The country shot down a patent extension on a critical TB drug.

by

You can count on the Prospect, can we count on you?

There's no paywall here. Your donations power our newsroom as we report on ideas, politics and power — and what’s really at stake as we navigate another presidential election year. Please, become a member, or make a one-time donation, today. Thank you!